ID   TU-OS-4
AC   CVCL_K032
SY   TUOS-4; Tottori University-Ovarian Serous-4
DR   Cosmic; 2482712
DR   Wikidata; Q54973333
RX   PubMed=21610153;
RX   PubMed=23274876;
CC   Population: Japanese.
CC   Doubling time: 53.3 +- 8.1 hours (PubMed=23274876).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 11
//
RX   PubMed=21610153; DOI=10.1158/1078-0432.CCR-11-0190;
RA   Itamochi H., Oishi T., Shimada M., Sato S., Uegaki K., Naniwa J.,
RA   Sato S., Nonaka M., Terakawa N., Kigawa J., Harada T.;
RT   "Inhibiting the mTOR pathway synergistically enhances cytotoxicity in
RT   ovarian cancer cells induced by etoposide through upregulation of c-Jun.";
RL   Clin. Cancer Res. 17:4742-4750(2011).
//
RX   PubMed=23274876; DOI=10.1007/s13577-012-0048-1;
RA   Itamochi H., Kato M., Nishimura M., Oishi T., Shimada M., Sato S.,
RA   Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N., Kigawa J.,
RA   Harada T.;
RT   "Establishment and characterization of a novel ovarian serous
RT   adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.";
RL   Hum. Cell 25:111-115(2012).
//